NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) Billions Opportunity w/ autism psilocybin

NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) CMO Marvin Hausman, M.D.: โ€œNovaโ€™s Psilocybin-based Therapeutics Showing Vast Potential for Autism and Other Neuroinflammatory Disordersโ€

Update onย  4/8/2022 livestream discussing clinical trial application to Health Canada for a Phase 2A study evaluating its psilocybin microdose therapy for Fragile X Syndrome, in the coming weeks.

NEXT SUPER STOCK: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA) is developing treatment for autism based on psilocybin with fast track potential to commercialization. Multi-billion dollar revenue potential with off-label use. Most importantly: $NMLSF team has proven track record bringing drugs through FDA process to market, (and generating +10X-50X returns for investors).

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.